Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | PDE8B | O95263 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476894 | 1.00 | PPARG (0.52) | PPARGPPARAPPARDPDE8BTP53 | |
| SCHEMBL4784306 | 0.84 | PPARG (0.66) | PPARGPPARAPPARDTP53FFAR1 | |
| SCHEMBL4784313 | 0.84 | PPARG (0.66) | PPARGPPARAPPARDTP53FFAR1 | |
| SCHEMBL16468191 | 0.83 | PPARG (0.55) | PPARGPPARAPPARDTP53ALDH1A1 | |
| SCHEMBL16468190 | 0.83 | PPARG (0.55) | PPARGPPARAPPARDTP53ALDH1A1 | |
| SCHEMBL12476895 | 0.83 | FFAR1 (0.50) | PPARGPPARAPDE8BFFAR1MAPT | |
| SCHEMBL15269982 | 0.80 | FAAH (0.51) | PPARGPPARAPDE8BTP53ALDH1A1 | |
| SCHEMBL15543185 | 0.78 | PPARG (0.55) | PPARGPPARAPPARDTP53FFAR1 | |
| SCHEMBL15543934 | 0.78 | PPARG (0.55) | PPARGPPARAPPARDTP53FFAR1 | |
| SCHEMBL4730360 | 0.78 | PPARG (0.66) | PPARGPPARAPPARDTP53FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | claimed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | claimed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | claimed |
| EP-2658851-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LTD (IN) | 2015-03-11 | — | — | EP | disclosed |
| US-8822414-B2 | Heterocyclic compounds suitable for the treatment of dyslipidemia | CADILA HEALTHCARE LIMITED (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281366-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | LIPC, HMGCR, PCSK9 | PPARG 161/4885PPARA 162/4885PPARD 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.